N/A N=50 Single-blind Diagnostic

Benefits Study of Respiratory-gated Positron Emission Tomography Acquisitions of the Liver

Liver Cancer

Bottom Line

View on ClinicalTrials.gov: NCT01219985 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Oct 2013

Primary outcome: Primary: Number of Detected Uptakes on PET Images — 47; 54; 74; 74 number of real metastatic lesions — p=<0.001

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: standard and respiratory-gated PET acquisitions (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Centre Hospitalier Universitaire, Amiens
Primary completion: Dec 2009

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Detected Uptakes on PET Images	47; 54; 74; 74	<0.001 sig
SECONDARY Lesions Uptake Measurement (SUVmax)	7.6; 8.5	<0.001 sig

Summary

Fluorodeoxyglucose (FDG) positron emission tomography (PET) is now widely used for cancer imaging purpose, notably for preoperative work-up. It aims at visualizing organs metabolism. In case of cancer, metabolism is, classically, increased and some hot spots are visible on PET images. Because of respiratory motion and because the liver is intrinsically FDG avid, some tumours (especially the smallest ones) can be occulted and missed by the clinician. The investigators developed a respiratory-gated PET method in order to reduce the motion issue. This protocol has been validated on lung pathologies. The investigators designed a study to investigate its effect on liver cancer (primary or metastasis) to check if it allows the detection of a higher number of tumour lesions. To that aim, patients who are planned to undergo a surgical intervention on the liver can be proposed to participate this study. After the standard PET acquisition (acquired in free-breathing), an additional 10 minutes respiratory-gated PET acquisition is performed without additional injection. After that, a breath-hold (~10s) CT is performed.

Eligibility Criteria

Inclusion Criteria

patient planed to undergo any liver surgical intervention
age : over 18
patients gave their written informed consent

Exclusion Criteria

pregnancy
liver surgical intervention cancel upon surgical or medical decision

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01219985). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.